Program Director
Khalid Al Rasadi, MD
Program Director
Raul D Santos, MD, MSc, PhD
2020 Middle East Summit on Residual Cardiovascular Risk
Cardiovascular diseases remain the #1 cause of death and disability globally and are on the rise in developing regions of the world. Despite advances in the control of the classic risk factors like lowering LDL-Cholesterol and efforts to manage contributing disease factors such as diabetes, obesity and hypertension, patient risk for developing ASCVD can still remain high. This course was designed to educate on the complete examination and clinical approaches to the treatment of residual risk (RR) factors that may persist and ultimately continue to drive the patient’s potential for cardiovascular events.
The IAS is pleased to present thirteen (13) recordings from the live accredited sessions presented at the 2020 Middle East Residual Risk Cardiovascular Summit held in Dubai on February 21-22, 2020. This comprehensive educational event was designed for medical professionals in the clinical setting.
The IAS is very grateful to Biologix FzCo for supporting the 2020 Middle East Residual Risk Cardiovascular Summit through an unrestricted educational grant. We also thank all the speakers and participants for sharing their experience and for helping IAS to develop this global faculty of experts featured in the presentations.
Pre-activity information
Target Audience
This 2020 Middle East Summit on Residual Cardiovascular Risk is a comprehensive educational campaign targeted to meet the educational needs of medical professionals in clinical practice engaged in the prevention or the management of patients demonstrating risk or with established cardiovascular disease.
Learning Objectives
By participating in these educational offerings, the learner is expected to be able to:
1) Identify opportunities to address ASCVD residual risk factors, including under-treatment of related conditions and non-LDL related risk conditions
2) Describe the association of LDL-C driven RR with ASCVD RR, including the role of intensive LDL lowering on risk reduction
3) Select evidence-based residual risk reduction interventions, including modifying TGL
4) Distinguish glucose-lowering agents associated with independent ASCVD risk reduction effects, including GLP-1 receptor agonists and SGLT2 inhibitors
5) List the pros and cons of more intensive blood pressure lowering with regards to RR
6) Describe the epidemiology and association of CKD especially in diabetic and or hypertensive individuals with cardiovascular disease
7) Recall the association of Lp(a) with ASCVD Risk, epidemiology, genetics and identify upcoming clinical trials exploring the use of specific Lp(a) inhibitors.
8) Identify biomarkers associated with inflammation-driven ASCVD RR, including CRP and design inflammation management plans to reduce RR, including exercise and weight loss
9) Describe the association of increased thrombotic RR with ASCVD, including the role of dual antiplatelet therapy, single antiplatelet or dual antiplatelet therapy plus low-dose NOAC in reducing RR
Faculty & Disclosures
The IAS is proud to present this esteemed global faculty. More information on each faculty member can be found here.
Khalid Al-Rasadi, MD
|
Disclosures |
Date of Disclosures |
|
Consultant or advisory board member from Astra Zeneca, Pfizer, Sanofi, Aegerion and Abbott. Grant and Research support received from Sanofi. |
22-02-2020 |
Raul D Santos, MD, MSc, PhD
|
Disclosures |
Date of Disclosures |
|
Honorarium for research activities from Amgen, Kowa, Esperion, Sanofi/Regeneron. Honorarium for speaker activities from Amgen, Ache, Astra Zeneca, Merck, MSD, Pfizer, PTC and Novo Nordisk. |
22-02-2020 |
Tarek M Fiad, MBBCh, FRCPI, FRCP, MD
There are no Disclosure Statements against this Module for Tarek M Fiad, MBBCh, FRCPI, FRCP, MD
Dr. Hani Sabbour, MD, FACC, FHRS, FASE
|
Disclosures |
Date of Disclosures |
|
Speakers Bureau: AZ, Abbott, Merck,Amgen, Aegerion,Sanofi |
22-02-2020 |
Dr. Rabih R. Azar, MD, MPH, FACC
|
Disclosures |
Date of Disclosures |
|
Commercial: Astra-Zeneca; Sanofi; Boehringer; Pfizer; Roche; MSD; Servier; Abbot; Boston Scientific. |
22-02-2020 |
Omar M. Hamoui, MD
|
Disclosures |
Date of Disclosures |
|
Educational Activities: Honoraria for Educational Activities, over 10 companies |
22-02-2020 |
Dr. Abdullah Shehab
There are no Disclosure Statements against this Module for Dr. Abdullah Shehab
Dr. Khalid Al Habib
There are no Disclosure Statements against this Module for Dr. Khalid Al Habib
Staff Disclosures
Staff involved with the development of this activity have nothing to disclose.
Moderator disclosures
Dr Fahad Al Nouri
|
Disclosures |
Date of Disclosures |
|
Advisory Board for: Amgen, Amryt; Lecturing for Amgen; Research grant from Amgen |
22-02-2020 |
Dr. Niaz Khan
There are no Disclosure Statements against this Module for Dr. Niaz Khan
Dr Wael Al Mahmeed
There are no Disclosure Statements against this Module for Dr. Wael Al Mahmeed
Dr Malek Mohamed
There are no Disclosure Statements against this Module for Dr. Malek Mohamed
Dr Abdul Majeed Brek Al Zubaidi
There are no Disclosure Statements against this Module for Dr. Malek Mohamed
Funding Information
The IAS is very grateful to Biologix FzCo for supporting the 2020 Middle East Residual Risk Cardiovascular Summit through an unrestricted educational grant. We also thank all the faculty and clinician attendees from throughout the Middle East who shared their experience and contributed to the IAS in its global mission.
References
When viewing each activity look for “Materials” tab to download PDF Slides
NAFLD/NASH and ASCVD Connection: Final Messages
Combined Patient Management
Patient Identification and Risk Stratification
ASCVD and NAFLD/NASH: the Background of the Connection
Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes?
Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes?
Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares
Parte 3, Sessão A – Uma hierarquia de abordagens de tratamento com base na gravidade para o paciente DM2 com DCVA
Parte 2 – Combatendo a aterosclerose: avaliando o risco CV para o paciente com DM2
Parte 1 – A história na batalha da insulina e glucagon
Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease
Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD
Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient
Part 1: The History in the Battle of Insulin and Glucagon
Modera resumen de los mensajes claves de las conferencias – Maria Cristina Izar (Brasil)
Discusión Foro 4 – Panelist Roopa Mehta (Mexico)
Nuevas terapias para la HF grave – Paola Varleta (Chile)
Eficacia y seguridad de Lomitapida en HF homocigota – Dirk Blom (SudAfrica)